Brief Summary

The objective of this observational study is to determine the prevalence of sarcopenia in patients aged 50 years and older with acute ischemic stroke, to characterize its trajectory during the acute phase using instrumental verification and functional-cognitive assessments, and to evaluate its impact on functional outcome at three months. The main research question is: Is the presence of sarcopenia at admission associated with less favorable stroke outcomes, including higher rates of complications and mortality? Participants receiving standard medical care for acute ischemic stroke will undergo extended functional assessment for sarcopenia, and a subset will additionally undergo cognitive evaluation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
42mo left

Started Aug 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress1%
Aug 2026Dec 2029

Study Start

First participant enrolled

August 1, 2026

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

August 4, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 13, 2026

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2029

Last Updated

August 13, 2026

Status Verified

July 1, 2026

Enrollment Period

3.4 years

First QC Date

August 4, 2026

Last Update Submit

August 12, 2026

Conditions

Keywords

sarcopeniaacute stroke

Outcome Measures

Primary Outcomes (2)

  • Change from Baseline in Barthel Index for Activities of Daily Living at 14 days

    Lower scores indicate increasing disability and a greater need for skilled care. Min - 0 ( \< 20 - totally dependent), max - 100 ( \> 80 - independent).

    Baseline and 14 days

  • Change from Baseline in Modified Rankin scale at 90 days

    Min - 0 (no disability), max - 6 (dead). A score of 0 is no disability, 5 is disability requiring constant care for all needs; 6 is death.

    Baseline and 90 days

Secondary Outcomes (11)

  • Number of Participants with sarcopenia

    Baseline

  • Change from Baseline in arm muscle mass at 14 and 28 days.

    Baseline, 14 and 28 days

  • Change from Baseline in calf circumference at 14 and 28 days

    Baseline, 14 and 28 days

  • Change from Baseline in handgrip strength at 14 and 28 days.

    Baseline, 14 and 28 days.

  • Correlations between anthropometric measures and ultrasound/CT parameters

    Baseline, 14, 28, and 90 days

  • +6 more secondary outcomes

Eligibility Criteria

Age50 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population comprises patients with acute ischemic stroke admitted within the first 72 hours after symptom onset.

You may qualify if:

  • Age 50 years and older
  • Acute ischemic stroke confirmed by CT or MRI
  • Admission within the first 72 hours
  • Written informed consent and availability of a contact telephone number for follow-up

You may not qualify if:

  • TIA without a visible lesion on neuroimaging; bilateral hemiparesis
  • Amputations or severe contractures that preclude anthropometric assessment
  • Active cancer at stage IV or life expectancy of less than 3 months
  • Neuromuscular diseases; chronic use of systemic glucocorticoids for more than 3 months
  • Pregnancy; refusal to participate
  • Discontinuation criteria (drop-out)
  • Discharge or death within the first 7 days
  • Withdrawal of consent
  • Transfer to another facility resulting in loss of contact

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"

Moscow, 115446, Russia

RECRUITING

MeSH Terms

Conditions

SarcopeniaStroke

Condition Hierarchy (Ancestors)

Muscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and SymptomsCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 4, 2026

First Posted

August 13, 2026

Study Start

August 1, 2026

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2029

Last Updated

August 13, 2026

Record last verified: 2026-07

Locations